Filing Overview
Registrant: TradeUP Acquisition Corp. (the filing relates to the proposed combination with Estrella Biopharma, Inc.; the requested company metadata identifies Estrella Immunopharma, Inc.). The Form 8-K was filed March 17, 2023, under Items 1.01, 2.03, 3.02, 8.01 and 9.01. It is not a periodic financial statement filing and does not report operating results for a quarterly or annual period.
Material Financial Terms
- Estrella Biopharma deposited $45,511 into TradeUP’s trust account to extend the deadline to complete the proposed business combination to April 19, 2023.
- The deposit is evidenced by an unsecured promissory note issued by TradeUP to Estrella Biopharma.
- The note bears no interest and is payable in full upon consummation of the business combination.
- If the transaction is terminated under the merger agreement, TradeUP must refund the principal amount to Estrella within five business days.
- Estrella may elect to convert all or part of the note into private shares at a conversion price of $10.00 per share, subject to the stated notice requirements.
- Any conversion shares are generally restricted from transfer or sale until 30 days after completion of the initial business combination, subject to limited exceptions, and carry registration rights.
Changes, Outlook and Risks
The principal change reported is the extension of the business-combination deadline through April 19, 2023, funded by the $45,511 extension payment. The filing does not provide revenue, profit, cash-flow, margin, total debt, cash balance, liquidity ratios or other operating metrics.
The note includes events of default covering failure to pay, bankruptcy, breach, cross-defaults, enforcement proceedings, and unlawfulness or invalidity of performance. Upon an event of default, the note may be accelerated. The proposed business combination remained subject to completion and could be terminated under the merger agreement.
The note and any related conversion shares were issued or may be issued under the Section 4(a)(2) exemption from Securities Act registration. The filing also includes a press release announcing the note issuance.
Investor Verification Items
- Verify whether the business combination was ultimately completed and whether the April 19, 2023 deadline was further extended.
- Confirm the final treatment of the $45,511 note, including repayment or conversion into shares.
- Review the merger agreement and Extension Note for termination, default, conversion and repayment provisions.
- Assess dilution and ownership implications if the note was converted at $10.00 per share.
- Confirm the identity of the relevant entity, because the filing registrant is TradeUP Acquisition Corp. and the merger counterparty named in the filing is Estrella Biopharma, Inc., while the request metadata references Estrella Immunopharma, Inc.